X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ABBOTT INDIA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ABBOTT INDIA DIVIS LABORATORIES/
ABBOTT INDIA
 
P/E (TTM) x 29.0 42.8 67.8% View Chart
P/BV x 5.0 10.7 47.0% View Chart
Dividend Yield % 1.0 0.6 157.0%  

Financials

 DIVIS LABORATORIES   ABBOTT INDIA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
ABBOTT INDIA
Mar-16
DIVIS LABORATORIES/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,2226,015 20.3%   
Low Rs7843,707 21.1%   
Sales per share (Unadj.) Rs153.11,236.9 12.4%  
Earnings per share (Unadj.) Rs39.9122.2 32.7%  
Cash flow per share (Unadj.) Rs44.6129.0 34.6%  
Dividends per share (Unadj.) Rs10.0035.00 28.6%  
Dividend yield (eoy) %1.00.7 138.5%  
Book value per share (Unadj.) Rs201.8521.2 38.7%  
Shares outstanding (eoy) m265.4721.25 1,249.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.63.9 166.7%   
Avg P/E ratio x25.139.8 63.1%  
P/CF ratio (eoy) x22.537.7 59.7%  
Price / Book Value ratio x5.09.3 53.3%  
Dividend payout %25.028.6 87.4%   
Avg Mkt Cap Rs m266,266103,296 257.8%   
No. of employees `0009.73.0 329.3%   
Total wages/salary Rs m4,6873,370 139.1%   
Avg. sales/employee Rs Th4,175.08,891.8 47.0%   
Avg. wages/employee Rs Th481.51,140.0 42.2%   
Avg. net profit/employee Rs Th1,089.3878.3 124.0%   
INCOME DATA
Net Sales Rs m40,64326,284 154.6%  
Other income Rs m749504 148.5%   
Total revenues Rs m41,39226,789 154.5%   
Gross profit Rs m14,4603,665 394.5%  
Depreciation Rs m1,233144 854.1%   
Interest Rs m238 279.0%   
Profit before tax Rs m13,9534,017 347.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,3491,421 235.7%   
Profit after tax Rs m10,6042,596 408.4%  
Gross profit margin %35.613.9 255.1%  
Effective tax rate %24.035.4 67.9%   
Net profit margin %26.19.9 264.1%  
BALANCE SHEET DATA
Current assets Rs m40,10514,446 277.6%   
Current liabilities Rs m6,5954,725 139.6%   
Net working cap to sales %82.537.0 222.9%  
Current ratio x6.13.1 198.9%  
Inventory Days Days11951 230.6%  
Debtors Days Days8120 412.5%  
Net fixed assets Rs m19,9951,113 1,796.7%   
Share capital Rs m531213 249.8%   
"Free" reserves Rs m53,04310,808 490.8%   
Net worth Rs m53,57411,076 483.7%   
Long term debt Rs m00-   
Total assets Rs m61,58516,241 379.2%  
Interest coverage x618.4497.0 124.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.71.6 40.8%   
Return on assets %17.316.0 107.6%  
Return on equity %19.823.4 84.4%  
Return on capital %26.136.3 71.8%  
Exports to sales %00.6 0.0%   
Imports to sales %25.212.6 199.7%   
Exports (fob) Rs mNA162 0.0%   
Imports (cif) Rs m10,2593,322 308.8%   
Fx inflow Rs m35,384268 13,202.9%   
Fx outflow Rs m10,3993,927 264.8%   
Net fx Rs m24,985-3,659 -682.8%   
CASH FLOW
From Operations Rs m11,4932,514 457.1%  
From Investments Rs m-11,372-800 1,422.3%  
From Financial Activity Rs m-93-803 11.6%  
Net Cashflow Rs m28912 3.1%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.8 7.9 149.4%  
FIIs % 19.0 0.1 19,000.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 17.1 100.6%  
Shareholders   31,796 18,270 174.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   TORRENT PHARMA  NATCO PHARMA  BIOCON LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 19, 2018 03:37 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS